Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
doi: 10.1124/jpet.108.149211
Eligible patients with type 2 diabetes lost an average of 6.4% of their body weight (-14.1 lbs) in a 40-week clinical trial evaluating 2.0 mg injectable semaglutide
Tirzepatide is administered through subcutaneous injection once a week
Low-level endotoxin exposure from injectable products can cause injection site inflammation, fever, malaise, and flu-like symptoms
Our physicians evaluate your health history, sleep patterns, and current lifestyle thoroughly
Semaglutide, sold as Wegovy for weight loss and Ozempic for diabetes, produces average weight loss of around 14.9 percent in trials
US$ 29.48
US$ 25.46
US$ 23.19
US$ 20.00
